A single intravenous dose of EMEND for Injection was shown to be superior to placebo when either were combined with other anti-vomiting agents for protection against CINV in patients receiving ...
Merck (MRK), known as MSD outside the United States and Canada, today announced results from a Phase 3 study investigating the safety and efficacy of single-dose EMEND® (fosaprepitant dimeglumine) for ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. EMEND IV contains the active ingredient fosaprepitant dimeglumine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results